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D
uring metastasis, tumor cells (as 
individuals or possibly in groups) 
depart the main body of a tumor 
and invade neighboring and remote tissues. 
Finding the right tools to investigate what 
drives cancerous cells to this invasive state 
and how they manage the invasion process 
has long been a knotty problem—one that 
Erik Sahai is determined to unpick.
Sahai is not the type to let a loose thread 
hang; instead, he’s apt to grab it and follow 
it through the tangle to see where it leads 
him. A problem he fi  rst grasped as a grad-
uate student—the ability of Rho small 
GTPases to regulate transformation via 
ROCK family kinases (1, 2)—eventually 
led Sahai to where he is today: tying his 
many observations together into a better 
understanding of invasive mechanisms 
(3–5). We called him at his lab at the Can-
cer Research UK London Research Insti-
tute to discuss how he’s approached this 
gnarly problem.
FIRST THREAD
When did you decide you wanted a 
career in science?
I wasn’t one of those kids who knew at age 
seven that they wanted to be a scientist. 
I think I didn’t really start 
considering it as a career 
until, as an undergraduate, I 
got a summer job working 
in Jon Pines’ lab in Cam-
bridge. I really enjoyed the 
atmosphere and the energy 
of being in a lab and doing 
experiments, but I also think 
science had the same appeal 
that just mucking around in the backyard 
had: playing with stuff, seeing what hap-
pens, and fi  guring out how things work.
What did you initially set out to work on 
in your graduate work?
When I did my PhD, I decided that I 
wanted to move to London because, as 
beautiful as Cambridge is, I was 20 years 
old and had become rather bored of the 
limited scope of activity outside the lab 
that Cambridge had to offer—I wanted 
to move to a big city. I joined Richard 
Treisman’s lab, which was focused on the 
serum response factor (SRF) pathway.
For my fi  rst project in his lab, I was ac-
tually trying to clone a gene that doesn’t 
exist. I was looking for the mammalian 
homologue of a yeast protein, Ste12, which 
interacts with the yeast homologue of SRF. 
Today, if you want to know whether there’s 
a mammalian Ste12, you can go on NCBI 
and work out that there isn’t one in 10 sec-
onds. But back then, genome sequencing 
hadn’t yet taken hold, and the Internet 
barely existed, so you had to try all sorts of 
other approaches. I think I spent 18 months 
or so looking for this gene with no success 
before switching projects.
After struggling through that experience, 
what did you do?
Although it was unsuccessful in the end, I 
actually learned quite a lot from trying 
many different techniques and also from 
constantly having to think up new ap-
proaches to solve the problem. But after 
that I switched to trying to understand 
how the Rho small G protein signals to 
SRF. The approach I took 
toward that was trying to 
make some Rho effector 
mutants, with the idea being 
that these would give us 
some insight into the differ-
ent things that Rho could 
regulate within the cell. Un-
fortunately, we weren’t able 
to link a particular Rho ef-
fector to signaling to SRF. Instead, the 
one interesting thing to come out of the 
project was the fact that the Rho proteins 
regulate cell transformation through the 
ROCK family kinases.
TYING UP LOOSE ENDS
So what did you work on as a postdoc?
In my PhD I’d observed that growth control 
could be restored in some transformed cells 
by a small-molecule ROCK inhibitor, which 
suggested Rho-ROCK signaling was im-
portant for Ras-mediated transformation. 
But if you surveyed the literature as a whole, 
there were several papers claiming the op-
posite. So there was this apparent paradox 
in the literature, and I liked the intellectual 
challenge of working that out. I suppose 
one could simply shrug one’s shoulders 
and say, “It’s a different cell line,” but I’ve 
never found that response particularly sat-
isfying. Therefore, assuming the experi-
ments have been done properly, the data 
should tell you something. It might not fi  t 
nicely into your favorite hypothesis, but so 
long as it’s not some aberration or artifact, 
then data are data and they have to be rec-
onciled. I think if you’re a scientist you 
can’t ignore experimental results. They 
have to fi  t in somewhere, somehow, even if 
you don’t understand how that is at the 
time that you get the results. It transpired 
that some aspects of Rho signaling promote 
the deregulated proliferation of transformed 
fi  broblasts while other Rho-regulated proc-
esses hinder transformation.
You also investigated how Rho-ROCK 
signaling regulates tumor cell invasion…
About the time I joined Chris Marshall’s 
lab for my postdoc, we were starting to play 
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Sahai uses 3D culture and intravital imaging to investigate how tumor 
cells invade surrounding tissues.
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“If you’re a 
scientist you 
can’t ignore 
experimental 
results.”
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around with Matrigel as a 3D matrix, 
which others had used to set up what I 
thought were more realistic types of inva-
sion assays—ones that weren’t simply 
cells crawling around in 2D. So we started 
putting cancer cell lines into these 3D 
matrices and doing invasion assays with 
the ROCK inhibitor, trying to work out 
whether the sensitivity of the cell line cor-
related with whether or not it had a Ras 
mutation or whether or not it had high 
MAP kinase signaling.
Another critical thing about those stud-
ies is that we were actually looking down 
the microscope at the cells to evaluate 
whether or not they were invading, as op-
posed to using assays that score invasion 
by swabbing one side of a fi  lter and mea-
suring the amount of cellular material pres-
ent. And while I don’t think we resolved 
the paradox for why 3D invasion by some 
cells is sensitive to ROCK inhibition while 
in other cells it’s not, we did learn some of 
the rules about how you could tell whether 
or not a cell line would require ROCK 
function to invade into a three-dimensional 
matrix. More generally, we learned that 
cancer cells can have different modes of 
invasion and that this has implications for 
therapeutic strategies to stop invasion.
How does ROCK drive invasion by 
cancer cells?
ROCK drives actomyosin contractility, 
which is responsible for the rounded mor-
phology we observe in some invading 
cells. We think the cell also utilizes acto-
myosin contractility to produce force with 
which to deform the extracellular matrix. 
So, if you think about the extracellular ma-
trix, it forms a barrier in front of tumor 
cells that keeps them from 
invading. One solution is to 
elbow it out of the way and 
squeeze through, and that’s 
what we think is going on 
to a signifi   cant degree in 
these contractile, ROCK-
dependent cells. The other 
solution to this problem is 
to chop the barrier up, and 
that’s what ROCK-inde-
pendent cells (which typi-
cally have a very different, 
elongated morphology) do. 
Both forms of invasion can be observed in 
vivo; cancers work pretty much every way 
that’s conceivable.
UNRAVELING COMPLEXITY
How did this lead you into intravital 
imaging?
There was a lingering question about what 
matrix material is closest to the physiologi-
cal environment and whether any of them 
actually represent a good model of a real 
tumor’s setting. At that time, 
John Condeelis’ lab had just 
published some of their ear-
ly intravital imaging of can-
cer cells moving around in 
their mammary tumor mod-
els. That technology was 
amazing and would enable 
me to answer my questions 
about whether reconstituted 
matrices mimic what’s going on in tumors. 
So I got a one-year fellowship to go work 
in the Condeelis lab and learn this tech-
nology before setting up my own lab.
What have you chosen to pursue in your 
own lab?
Our intravital imaging has revealed that 
there is great heterogeneity in behavior 
within tumors: some cells invade, many 
don’t. The causes and consequences of this 
heterogeneity represent an interesting bio-
logical problem and probably relate to the 
uneven response of tumors to therapy. One 
thing we wanted to probe was whether par-
ticular transcriptional programs might be 
heterogeneously active within the tumor—
we’ve obtained some interesting insights 
by simultaneously imaging cell behavior 
and transcriptional readouts.
Another area we’ve been working on is 
the heterogeneous interactions between the 
tumor and its environment, focusing on 
cancer-associated fi  broblasts and how they 
might promote invasion. For example, we 
observed that the cancer-associated fi  bro-
blast acts as the leading cell of a cohort of 
tumor cells. It clears a path through the 
surrounding tissue, like a snowplow clear-
ing a track for other cars to 
use. This process therefore 
starts to resemble aspects of 
developmental biology and 
morphogenesis and poses in-
teresting questions concern-
ing how cells move when 
there’s a whole group of 
them moving together. For 
example, how is movement 
coordinated and organized? And how do 
cancer cells trick fi  broblasts into doing 
their dirty work for them?
We’re watching tumors in all their 
complexity, then trying to unpick what’s 
going on. Hopefully we can learn a lot 
more and make a small contribution to 
the benefi  t of cancer patients.
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Melanoma cells (green) invading into a collagen-rich matrix 
(blue) containing phagocytic cells (red).
“Cancers 
work pretty 
much every 
way that’s 
conceivable.”
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Sahai and postdoc Fernando Calvo discuss a 
recent result.